Nextage Financial Statements From 2010 to 2024
| MCTC Stock | ILA 78.50 3.00 3.97% |
Check Nextage Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nextage Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Nextage financial statements analysis is a perfect complement when working with Nextage Therapeutics Valuation or Volatility modules.
Nextage |
Nextage Therapeutics Company Profit Margin Analysis
Nextage Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Nextage Therapeutics Profit Margin | (2.30) % |
Most of Nextage Therapeutics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nextage Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Nextage Therapeutics has a Profit Margin of -2.3036%. This is 79.45% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The profit margin for all Israel stocks is 81.39% higher than that of the company.
Nextage Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nextage Therapeutics's current stock value. Our valuation model uses many indicators to compare Nextage Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nextage Therapeutics competition to find correlations between indicators driving Nextage Therapeutics's intrinsic value. More Info.Nextage Therapeutics is regarded fourth in return on asset category among its peers. It also is regarded fourth in profit margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nextage Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nextage Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Nextage Therapeutics Financial Statements
Nextage Therapeutics stakeholders use historical fundamental indicators, such as Nextage Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Nextage Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Nextage Therapeutics' assets and liabilities are reflected in the revenues and expenses on Nextage Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Nextage Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nextage Stock
Nextage Therapeutics financial ratios help investors to determine whether Nextage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nextage with respect to the benefits of owning Nextage Therapeutics security.